Profilaxis, diagnóstico y tratamiento | 07 ABR 14

Migraña crónica

Frecuencia, factores adversos asociados con la transformación a la migraña crónica, su carga individual y social y, diagnóstico.
Autor/a: Dr. Todd J Schwedt BMJ 2014;348:g1416
INDICE:  1.  | 2. Referencias

1    Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609.
2    2 Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52:1456-70.
3    3 Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157-68.
4    4 Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006;67:252-7.
5    5 Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain 2013;136:3489-96.
6    6 Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache 2008;48:16-25.
7    7 Scher AI, Stewart WF, Buse D, Krantz DS, Lipton RB. Major life changes before and after the onset of chronic daily headache: a population-based study. Cephalalgia 2008;28:868-76.
8    8 Davies P. Medication overuse headache: a silent pandemic. Pain 2012;153:7-8.
9    9 Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt IW, et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999;22:201-6.
10    10 Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002;59:1011-4.
11    11 Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013;53:1548-63.
12    12 Starling AJ, Hoffman-Snyder C, Halker RB, Wellik KE, Vargas BB, Dodick DW, et al. Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Neurologist 2011;17:297-9.
13    13 Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011;76:711-8.
14    14 Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
15    15 Stovner LJ, Andree C. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain 2008;9:139-46.
16    16 Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54.
17    17 Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010;81:428-32.
18    18 Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559-66.
19    19 Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 2012;52:3-17.
20    20 Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache 2011;51:1058-77.
21    21 Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-15.
22    22 Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2009;49:498-508.
23    23 Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 2010;52:8-14.
24    24 Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache 2007;47:996-1003; discussion 1004-7.
25    25 Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One 2008;3:e3799.
26    26 Schwedt TJ, Larson-Prior L, Coalson RS, Nolan T, Mar S, Ances BM, et al. Allodynia and descending pain modulation in migraine: a resting state functional connectivity analysis. Pain Med 2014;15:154-65.
27    27 Aurora SK. Spectrum of illness: understanding biological patterns and relationships in chronic migraine. Neurology 2009;72(5 suppl):S8-13.
28    28 Aurora SK. Is chronic migraine one end of a spectrum of migraine or a separate entity? Cephalalgia 2009;29:597-605.
29    29 Aurora SK, Kulthia A, Barrodale PM. Mechanism of chronic migraine. Curr Pain Headache Rep 2011;15:57-63.
30    30 Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache 2005;45:546-52.
31    31 Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine—classification, characteristics and treatment. Nat Rev Neurol 2011;8:162-71.
32    32 Kim JH, Suh SI, Seol HY, Oh K, Seo WK, Yu SW, et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia 2008;28:598-604.
33    33 Maleki N, Becerra L, Nutile L, Pendse G, Brawn J, Bigal M, et al. Migraine attacks the basal ganglia. Mol Pain 2011;7:71.
34    34 Schmitz N, Admiraal-Behloul F, Arkink EB, Kruit MC, Schoonman GG, Ferrari MD, et al. Attack frequency and disease duration as indicators for brain damage in migraine. Headache 2008;48:1044-55.
35    35 Valfre W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry reveals gray matter abnormalities in migraine. Headache 2008;48:109-17.
36    36 De Tommaso M, Losito L, Difruscolo O, Libro G, Guido M, Livrea P. Changes in cortical processing of pain in chronic migraine. Headache 2005;45:1208- 18.
37    37 Mongini F, Keller R, Deregibus A, Barbalonga E, Mongini T. Frontal lobe dysfunction in patients with chronic migraine: a clinical-neuropsychological study. Psychiatry Res 2005;133:101-6.
38    38 Schwedt TJ, Schlaggar BL, Mar S, Nolan T, Coalson RS, Nardos B, et al. Atypical resting-state functional connectivity of affective pain regions in chronic migraine. Headache 2013;53:737-51.
39    39 Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013;81:1191-6.
40    40 The International Classification of Headache Disorders, 3rd ed (beta version). Cephalalgia 2013;33:629-808.
41    41 Bigal ME, Lipton RB. The differential diagnosis of chronic daily headaches: an algorithm-based approach. J Headache Pain 2007;8:263-72.
42    42 Welch KM, Goadsby PJ. Chronic daily headache: nosology and pathophysiology. Curr Opin Neurol 2002;15:287-95.
43    43 Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, et al. Migraine and cardiovascular disease: a population-based study. Neurology 2010;74:628-35.
44 Chen YC, Tang CH, Ng K, Wang SJ. Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain 2012;13:311- 9.
45 De Tommaso M, Sardaro M, Serpino C, Costantini F, Vecchio E, Prudenzano MP, et al. Fibromyalgia comorbidity in primary headaches. Cephalalgia 2009;29:453-64.
46 Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 2010;30:129-36.
47 Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, et al. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res 2008;64:573-82.
48 Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 2010;123:612-24.
49 Teixeira AL, Costa EA, da Silva AA Jr, dos Santos IA, Gomez RS, Kummer A, et al. Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples. J Headache Pain 2012;13:551-5.
50 Verrotti A, Agostinelli S, D’Egidio C, Di Fonzo A, Carotenuto M, Parisi P, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol 2013;20:394-7.
51 Hershey AD, Powers SW, Nelson TD, Kabbouche MA, Winner P, Yonker M, et al. Obesity in the pediatric headache population: a multicentre study. Headache 2009;49:170-7.
52 Narin SO, Pinar L, Erbas D, Ozturk V, Idiman F. The effects of exercise and exercise-related changes in blood nitric oxide level on migraine headache. Clin Rehabil 2003;17:624-30.
53 Pryse-Phillips WE, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ 1998;159:47-54.
54 Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia 2011;31:1428-38.
55 Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814-23.
56 Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47:170-80.
57 Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-4.
58 Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
59 Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51:1358-73.
60 Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-14.
61 Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36.
62 Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008;9:37-41.
63 Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003;61:1753-9.
64 Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002;42:470-82.
65 Magalhaes E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010;112:463-6.
66 Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez- Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol 2010;33:35-9.
67 Edvardsson B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springerplus 2013;2:479.
68 Pascual-Gomez J, Alana-Garcia M, Oterino A, Leira R, Lainez-Andres JM. [Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate]. Rev Neurol 2008;47:449-51.
69 Bigal M, Rapopot A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache 2008;48:1337-42.
70 Peterlin BL, Calhoun AH, Siegel S, Mathew NT. Rational combination therapy in refractory migraine. Headache 2008;48:805-19.
71 Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology 2012;78:976-84.
72 Andrasik F. Behavioral treatment of migraine: current status and future directions. Expert Rev Neurother 2004;4:403-13.
73 Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain 2007;128:111-27.
74 Pistoia F, Sacco S, Carolei A. Behavioral therapy for chronic migraine. Curr Pain Headache Rep 2013;17:304.
75 Yang CP, Chang MH, Liu PE, Li TC, Hsieh CL, Hwang KL, et al. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia 2011;31:1510-21.
76 Irimia P, Palma JA, Fernandez-Torron R, Martinez-Vila E. Refractory migraine in a headache clinic population. BMC Neurol 2011;11:94.
77 Martin NJ, Holroyd KA, Penzien DB. The headache-specific locus of control scale: adaptation to recurrent headaches. Headache 1990;30:729-34.
78 Scharff L, Turk DC, Marcus DA. The relationship of locus of control and psychosocial-behavioral response in chronic headache. Headache 1995;35:527-33.
79 Hagen K, Albretsen C, Vilming ST, Salvesen R, Gronning M, Helde G, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia 2009;29:221-32.
80 Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006;26:1192-8.
81 Melo-Carrillo A, Lopez-Avila A. A chronic animal model of migraine, induced by repeated meningeal nociception, characterized by a behavioral and pharmacological approach. Cephalalgia 2013;33:1096- 105.
82 Oshinsky ML, Gomonchareonsiri S. Episodic dural stimulation in awake rats: a model for recurrent headache. Headache 2007;47:1026-36.
83 Pusic AD, Grinberg YY, Mitchell HM, Kraig RP. Modeling neural immune signaling of episodic and chronic migraine using spreading depression in vitro. J Vis Exp 2011;(52). pii: 2910.
84 Stucky NL, Gregory E, Winter MK, He YY, Hamilton ES, McCarson KE, et al. Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache 2011;51:674-92.
85 Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 2013;93:78-85.
86 Rapoport AM. The therapeutic future in headache. Neurol Sci 2012;33(suppl 1):S119-25.
87 Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013;80:697-704.
88 Oh MY, Ortega J, Bellotte JB, Whiting DM, Alo K. Peripheral nerve stimulation for the treatment of occipital neuralgia and transformed migraine using a c1-2-3 subcutaneous paddle style electrode: a technical report. Neuromodulation 2004;7:103-12.
89 Popeney CA, Alo KM. Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 2003;43:369-75.
90 Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;31:271- 85.
91 Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache--long-term safety and efficacy. Cephalalgia 2007;27:153-7.
92 Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012;32:1165-79.
93 Hann S, Sharan A. Dual occipital and supraorbital nerve stimulation for chronic migraine: a single-center experience, review of literature, and surgical considerations. Neurosurg Focus 2013;35:E9.
94 Reed KL, Black SB, Banta CJ 2nd, Will KR. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 2010;30:260-71.
95 Cecchini AP, Mea E, Tullo V, Curone M, Franzini A, Broggi G, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data. Neurol Sci 2009;30(suppl 1):S101-4.
96 Lipton RB, Pearlman SH. Transcranial magnetic simulation in the treatment of migraine. Neurotherapeutics 2010;7:204-12.
97 Teepker M, Hotzel J, Timmesfeld N, Reis J, Mylius V, Haag A, et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia 2010;30:137-44.
98 Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarinia M. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 2009;49:983-9.
99 Chepla KJ, Oh E, Guyuron B. Clinical outcomes following supraorbital foraminotomy for treatment of frontal migraine headache. Plast Reconstr Surg 2012;129:656e-62e.
100 Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg 2005;115:1-9.
101 Guyuron B, Kriegler JS, Davis J, Amini SB. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg 2011;127:603-8.
102 Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S. A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg 2009;124:461-8.
103 Loder E, Weizenbaum E, Frishberg B, Silberstein S. Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache 2013;53:1651-9.
104 Mathew PG. A critical evaluation of migraine trigger site deactivation surgery. Headache 2014;54:142-52.
105 Bussone G. Clinical considerations on chronic migraine, pharmacoresistance and refractoriness. Neurol Sci 2010;31(suppl 1):S83-5.
106 D’Amico D, Leone M, Grazzi L, Bussone G. When should “chronic migraine” patients be considered “refractory” to pharmacological prophylaxis? Neurol Sci 2008;29(suppl 1):S55-8.
107 Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache 2008;48:778-82.
108 Schulman EA, Peterlin BL, Lake AE 3rd, Lipton RB, Hanlon A, Siegel S, et al. Defining refractory migraine: results of the RHSIS survey of American Headache Society members. Headache 2009;49:509-18.
109 Giacomozzi AR, Vindas AP, da Silva AA Jr, Bordini CA, Buonanotte CF, Roesler CA, et al. Latin American consensus on guidelines for chronic migraine treatment. Arq Neuropsiquiatr 2013;71:478-86.
110 Straube A, Gaul C, Forderreuther S, Kropp P, Marziniak M, Evers S, et al. [Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society]. Nervenarzt 2012;83:1600-8.
111 Treatment Guideline Subcommittee of the Taiwan Headache Society. [Treatment guidelines for preventive treatment of migraine]. Acta Neurol Taiwan 2008;17:132-48.
112 Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol 2009;16:968-81.
113 Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53.
114 Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012;39(2 suppl 2):S1-59.
115 Ravishankar K, Chakravarty A, Chowdhury D, Shukla R, Singh S. Guidelines on the diagnosis and the current management of headache and related disorders. Ann Indian Acad Neurol 2011;14(suppl 1):S40-59.
116 Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 2012;13(suppl 2):S31-70.
117 Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62.
118 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45.
119 Vukovic Cvetkovic V, Kes VB, Seric V, Solter VV, Demarin V, Janculjak D, et al. Report of the Croatian Society for Neurovascular Disorders, Croatian Medical Association. Evidence based guidelines for treatment of primary headaches—2012 update. Acta Clin Croat 2012;51:323-78.
120 Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52:930-45.
121 Martelletti P, Jensen RH, Antal A, Arcioni R, Brighina F, de Tommaso M, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain 2013;14:86.
122 Tfelt-Hansen P, Pascual J, Ramadan N, Dahlof C, D’Amico D, Diener HC, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32:6-38.
123 Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-95.
124 Houle TT, Turner DP, Houle TA, Smitherman TA, Martin V, Penzien DB, et al. Rounding behavior in the reporting of headache frequency complicates headache chronification research. Headache 2013;53:908-19.
125 Houle TT, Turner DP, Smitherman TA, Penzien DB, Lipton RB. Influence of random measurement error on estimated rates of headache chronification and remission. Headache 2013;53:920-9.
126 Lipton RB, Penzien DB, Turner DP, Smitherman TA, Houle TT. Methodological issues in studying rates and predictors of migraine progression and remission. Headache 2013;53:930-4.
127 Turner DP, Smitherman TA, Penzien DB, Lipton RB, Houle TT. Rethinking headache chronification. Headache 2013;53:901-7.



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021